Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rF-PSA
- Development stage
- Unknown
- Lead developer
- Therion Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
rF-PSA is a recombinant fowlpox viral vector cancer vaccine engineered to express human prostate-specific antigen, intended to stimulate PSA-directed cellular immune responses against prostate cancer cells. In the provided clinical-trial context, it is used as the fowlpox booster component of a PSA-based prime-boost vaccine regimen, typically following vaccinia-based priming, in patients with localized prostate cancer receiving radiotherapy. The agent functions as a therapeutic cancer vaccine rather than a standalone cytotoxic drug, and its public-source use is most closely associated with National Cancer Institute-led studies of PSA-targeted poxviral immunotherapy programs related to the PROSTVAC platform.
- Other names
- rF-PSArecombinant fowlpox-PSA vaccinefowlpox virus plus human DNA that produces prostate-specific antigen
02
Targets
PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on rF-PSA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rF-PSA.